Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.

Bibliographic Details
Main Authors:	Shipman, C, Holen, I, Lippitt, J, Vandenberghe, E, Croucher, P
Format:	Journal article
Published:	2000

Similar Items

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
by: Shipman, C, et al.
Published: (2000)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
by: De Leenheer, E, et al.
Published: (2002)

Investigation of osteoclastogenic signalling of the RANKL substitute LIGHT
by: Hemingway, F, et al.
Published: (2013)

Investigation of osteoclastogenic signalling of the RANKL substitute LIGHT.
by: Hemingway, F, et al.
Published: (2013)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
by: Shipman, C, et al.
Published: (2002)

Bisphosphonates and in vivo models of multiple myeloma - Reply
by: Shipman, C, et al.
Published: (2001)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
by: Croucher, P, et al.
Published: (2001)

Anti-tumour activity of bisphosphonates in human myeloma cells.
by: Shipman, C, et al.
Published: (1998)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
by: Shipman, C, et al.
Published: (2000)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
by: Croucher, P, et al.
Published: (2001)

Bisphosphonates--mechanisms of action in multiple myeloma.
by: Shipman, C, et al.
Published: (2000)

The clinical significance of soluble human leukocyte antigen class-I, ICTP, and RANKL molecules in multiple myeloma patients.
by: Schütt, P, et al.
Published: (2008)

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.
by: Shipman, C, et al.
Published: (1997)

Osteoprotegerin and the development of myeloma bone disease
by: Croucher, P, et al.
Published: (2004)

Expression of osteoclastogenic markers in inflamed synovial tissues in prosthesis loosening and arthritis
by: Sabokbar, A, et al.
Published: (2001)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
by: Croucher, P, et al.
Published: (2001)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
by: Croucher, P, et al.
Published: (2000)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
by: Croucher, P, et al.
Published: (2002)

Rankl expression as a prognostic marker in stage III giant cell tumour of the bone
by: Abdul Ghani , Nur Sabrina
Published: (2015)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
by: Shipman, C, et al.
Published: (2003)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
by: Croucher, P, et al.
Published: (2003)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
by: Shipman, C, et al.
Published: (2002)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
by: Vanderkerken, K, et al.
Published: (2003)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
by: Shipman, C, et al.
Published: (2002)

Telomere length is a critical determinant for survival in multiple myeloma
by: Hyatt, S, et al.
Published: (2017)

Osteoblasts protect multiple myeloma cells from T-cell-induced apoptosis
by: Locklin, R, et al.
Published: (2007)

Ewing sarcoma cells express RANKL and support osteoclastogenesis
by: Taylor, R, et al.
Published: (2011)

Ewing sarcoma cells express RANKL and support osteoclastogenesis.
by: Taylor, R, et al.
Published: (2011)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
by: Holen, I, et al.
Published: (2002)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
by: Locklin, R, et al.
Published: (2005)

Serum separation abnormality in a multiple myeloma patient
by: Zaharudin, Mohd Radzli, et al.
Published: (2023)

The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
by: Shipman, C, et al.
Published: (1998)

Advances in the management of myeloma bone disease.
by: Shipman, C, et al.
Published: (2005)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
by: Croucher, P, et al.
Published: (2002)

RANKL-dependent and RANKL-independent mechanisms of macrophage-osteoclast differentiation in breast cancer.
by: Lau, Y, et al.
Published: (2007)

Animal models of multiple myeloma
by: Olechnowicz, SWZ, et al.
Published: (2019)

OPG is a survival factor for breast- and prostate cancer cells in vitro
by: Holen, I, et al.
Published: (2002)

Apomine, an inhibitor of HMG-COA-reductase, does not act by inhibiting protein prenylation in human myeloma cells in vitro
by: Roelofs, A, et al.
Published: (2005)

Myeloma cells decrease EphB4 expression in osteoblasts; A novel mechanism for regulation of bone formation in multiple myeloma
by: Bates, A, et al.
Published: (2007)

Myeloma cells decrease EphB4 expression in osteoblasts: A novel mechanism for regulation of bone formation in multiple myeloma
by: Bates, A, et al.
Published: (2007)